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Abstract Human hepatitis B virus, the leading pathogen for
hepatitis B, is a compact DNA virus with viral genes that largely
overlap. An increasing number of mutations have emerged
following human interventions such as vaccination and anti-viral
therapy. While vaccine escape mutants are characterized by
mutations on the antigenic hepatitis B surface antigen, those
carrying mutations in other viral proteins are either resistant to
anti-viral therapy or implicated in acute liver diseases. Molecular
identification of these various mutants should shed new lights on
the underlying mechanism of hepatitis B virus viral escape and
resistance and provide helpful information on their effective
eradication.
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1. Introduction
Hepatitis B remains a global health problem with a consid-
erable morbidity and mortality. It is estimated that there are
currently more than 350 million carriers worldwide. Hepatitis
B virus (HBV) causes a variety of acute and chronic human
liver diseases including fatal fulminant hepatitis, cirrhosis and
hepatocellular carcinoma (HCC), that is one of the most com-
mon human cancers [1]. Belonging to the family of hepadna-
virus, HBV is a partially double-stranded DNA virus that
replicates through an RNA intermediate by reverse transcrip-
tion [2]. The DNA genome of 3.2 kb is enveloped in a spheric
virion that is composed of an outer envelope and an inner
nucleocapsid. One particular characteristic of the HBV ge-
nome is its compact organization with four overlapping
open reading frames (ORFs) encoding DNA polymerase,
HBV surface antigen (HBsAg) core and HBX, respectively
(Fig. 1). This compact genomic organization provides con-
straints on the number of mutations that occur naturally dur-
ing viral replication, as some of them located within one ORF
(e.g. HBsAg) generate concurrent mutations in the overlap-
ping ORF (e.g. DNA polymerase) that may a¡ect the viability
of the virus.
Human interventions in preventing HBV have been focused
on the preventive neutralization of the circulating viral par-
ticles and the therapeutic inhibition of the viral replication.
While prevention was made possible by the HBV vaccines that
induce protective anti-HBs antibodies targeting the most anti-
genic region of HBsAg [3], promising advances on viral inhi-
bition have been made using nucleoside analogs that either
inhibit the DNA synthesis by terminating the nascent proviral
DNA or prevent the priming of HBV DNA polymerase to the
RNA template [4].
These control measures have led to a marked reduction of
the number of HBV carriers in the general population. How-
ever, various HBV mutants are being identi¢ed. These mu-
tants are either capable of escaping neutralization by HB vac-
cines or are resistant to anti-viral agents. Unlike the naturally
occurring HBV mutants that are often ‘silently’ present in
chronic carriers, these newly discovered variants are located
within functional domains of viral proteins and are now
linked to various stages of liver diseases, including the acute
hepatitis and the development of HCC.
Our review aims at giving a molecular overview of these
mutants which in turn may provide helpful information on
the design of a more e¡ective vaccine and therapeutic agents.
2. Hepatitis B surface antigen and mutants
The HBV viral envelope is composed of cellular lipids and
three related proteins, the large (L, preS1+preS2+HBsAg),
middle (M, preS2+HBsAg) and small (S, HBsAg) surface
antigens [5]. They are encoded by a single ORF of the HBV
genome and the translation is initiated at separate in-frame
ATG codons that are located at 118 and 55 amino acid res-
idues from each other. The corresponding translated products
are conventionally designated as LHBsAg, MHBsAg and
SHBsAg and are completely contained within the HBV
DNA polymerase (Fig. 2A).
The LHBsAg consisting of 400 amino acid residues con-
tains the hepatocyte binding site (amino acid residues 21^47)
and is involved in the attachment of HBV to hepatocytes [6,7].
The LHBsAg is also essential for virion assembly and the
intracellular level of LHBsAg a¡ects the secretion of viral
particles [8]. Retention of the over-expressed LHBsAg in the
endoplasmic reticulum may lead to the development of HCC
in transgenic mice. Similarly, such a retention results in the
‘ground glass’ cells that are present in some human chronic
HBV carriers ([5], Table 1). A role of LHBsAg in protective
immunity is also suggested by the presence of both B- and
T-cell epitopes [9]. Besides taking structural part in the HBV
envelope, C-terminal truncated but not the full-length
LHBsAg protein that is translated from HCC-integrated
HBV appears to function as a general transcriptional activa-
tor and may have a role in the development of HCC [10].
On the other hand, the MHBsAg of 281 amino acid resi-
dues appears to be dispensable for HBV virion assembly.
While rearrangement or deletion mutants have been identi¢ed
in LHBsAg in chronic HBV carriers [11], a missense mutation
at an initiation codon of MHBsAg is found in certain chronic
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carriers in Mediterranean countries [12] and also in patients
with fulminant hepatitis [13] and HCC (Singapore patient of
Oon strain, Table 1). Although HBV DNA polymerase over-
laps the entire LHBsAg, it is interesting to note that preS1/S2
fall within the spacer domain and SHBsAg within the reverse
transcriptase domain (Fig. 2A and B). This could explain the
observed alterations within the preS region, as the concurrent
changes in the spacer domain of the DNA polymerase that
has no de¢ned function would not a¡ect much HBV viral
replication.
The SHBsAg is a hydrophobic protein consisting of
226 amino acid residues and is the predominant component
of the viral envelope. The topology structure of LHBsAg is
assumed to display an outer (on the surface of the viral par-
ticle) or inner disposition of the N-terminus and an outer
disposition of the C-terminus [14]. The major hydrophilic re-
gion of HBsAg has been de¢ned from residue 100 to 160 in
SHBsAg (or 275^335 in LHBsAg) [13]. This hydrophilic re-
gion has an assumed two-loop structure and is located on the
surface of the viral particle (Fig. 3A). De¢ned as the ‘a’ deter-
minant [15], this two-loop structure encompassing residues
124^147 in SHBsAg is conserved in all HBV genotypes and
is directly involved in inducing neutralizing antibodies. It also
constitutes the basis of current HB vaccines.
The clinical clearance of serum HBV following vaccination
is characterized by the disappearance of HBsAg and a con-
comitant appearance of neutralizing anti-HBs antibodies, in-
duced by the vaccine. However, incidence of co-existence of
both HBsAg and anti-HBs has been observed following vac-
cination [16]. Emergence of HBV mutants capable of escaping
the neutralization by anti-HBs is indicated by the persistence
of HBsAg despite vaccination. The ¢rst case was reported
from Italy with the presence of a Gly-145-Arg mutation on
the HBsAg in the patient’s serum [16]. A similar serological
pro¢le has subsequently led to the identi¢cation of this and
other vaccine escape HBsAg mutants in other parts of the
world [17^26].
In Singapore, for example, sequence analysis of serum viral
DNA identi¢ed mutations on various positions of the ‘a’ de-
terminant of HBsAg in 41 vaccinated infants with a break-
through HBV infection [18]. These included Gly-145-Arg,
Asp-144-Ala, Met-133-Leu, Gln-129-His and Ile/Thr-126-Ala
[11]. The emergence of vaccine escape HBsAg mutants was
also con¢rmed from Japan and China [20,22,27]. While the
Gly-145-Arg mutants were identi¢ed in HBsAg and anti-HBs
co-existing serum, Ile-126-Thr was detected either in infants
without HBV infection or in those who developed acute hep-
atitis ([20], Table 1). In addition, the Thr-126-Ala mutation
was also identi¢ed in a vaccinated Taiwanese infant who de-
veloped fulminant hepatitis ([19], Table 1). Vaccine escape
HBsAg mutants have also been found in Spain [23], England
[24], Gambia [25], Zimbabwe [26], Germany [17] but at a low-
er frequency as compared with many Asian countries.
Identi¢cation of vaccine escape HBsAg mutants following
HBV vaccination from various countries indicated that muta-
Fig. 1. Genomic localization of HBV viral proteins. The location of
individual HBV viral protein (HBsAg, DNA polymerase, core and
HBX) is shown on the circular HBV genome (adapted from [73]
with permission). The arrows indicate the direction of translation
and the numbers represent the nucleotide position of the start (e.g.
1374 for HBX) and stop (e.g. 1835 for HBX) codons. Numbering
of the HBV genome (serotype adw) starts at the internal EcoRI site
near the junction of preS1 and preS2.
Table 1
HBV mutants and liver diseases
Viral protein/promoter Mutation Liver diseases Reference
SHBsAg Gly-145-Arg HCC [37,38]
Gly-145-Arg Acute hepatitis [19,36]
Met-133-Thr HCC [37]
Met-133-Leu HCC [28]
Gly-130-Asn HCC [38]
Ile-126-Thr Acute hepatitis [20]
Ile-126-Ser HCC [38]
PreS1 in LHBsAg Overexpression Ground glass leading to HCC [5]
Gln-10-Lys HCC [38]
PreS2 in MHBsAg Missense mutation at start codon HCC [38], unpublished data
Missense mutation at start codon Fulminant hepatitis [13]
Internal deletions HCC [38]
Phe-22-Leu HCC [38]
Precore/core Trp-28-stop codon Acute hepatitis, HCC [38,58]
Pro-130-Thr HCC [38]
Core promoter Nucleotide mutations (T1762, A1764) Fulminant hepatitis [52]
Nucleotide mutations (T1762, A1764) HCC [38]
HBX C-terminal insertions/deletions HCC [38], unpublished data
HBV genome* Integration in host chromosomes HCC [74]
*HBV genomes have been found integrated in the host genomes of most HBV-related HCC.
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tions were mainly occurring on the most antigenic ‘a’ deter-
minant. Many of these mutations resulted in changes in their
antigenic properties by computer-aided analysis [28], as illus-
trated in Fig. 3B for the most commonly reported mutation,
Gly-145-Arg. Such changes in turn result in a decreased in
vitro binding a⁄nity to neutralizing antibodies [29].
Recent evidence from Singapore [30] and Japan [20] also
suggested that some vaccine escape mutants carried mutations
on other parts of HBsAg. The fact that these HBsAg mutants
show an altered binding a⁄nity to neutralizing antibodies
[15,30] and the intriguing observation that preS2 containing
vaccines induced mutations on the major hydrophilic region
[31] appear to support the more complex structure of HBsAg.
In such a complex structure, HBsAg displays clusters of anti-
genic epitopes, some of which are located in the region span-
ning amino acid 160^207 [32].
In addition to their detection in vaccinated infants, the
HBsAg mutants may arise in patients with HBV infection
but diagnosed negative for HBsAg and the recipients for or-
thotopic liver transplantation [33]. Naturally occurring
HBsAg mutants have now been detected in a general popula-
tion albeit that their incidence remains low [28]. Although it
may take decades before the vaccine escape mutants become
predominant over the wild-type HBV [34], an improvement of
the current detection systems is needed as these mutants are
able to cause liver diseases in both chimpanzees and humans
[35,36] and are found in many HCC samples ([37,38], Table
1).
3. HBV DNA polymerase and mutants
While clinically relevant mutations on HBsAg are mainly
related to vaccination, other signi¢cant mutations detected in
HBV viral proteins include those in the HBV DNA polymer-
ase following prolonged treatment with nucleoside analogs
(i.e. lamivudine and famcyclovir) [4].
The HBV DNA polymerase consists of 832 amino acids
and is composed of four functional domains [39]. The ami-
no-terminal region (residue 1^178) is involved in priming the
viral template. Separated by a spacer region of 158 amino acid
residues (residues 179^336), the HBV DNA polymerase (span-
ning residues 337^680) possesses dual RNA- and DNA-de-
pendent polymerase activity while the RNAse H domain (res-
idue 681^832) is located at the C-terminus (Fig. 2B).
Unlike HBsAg mutants, mutations in the catalytic domain
of the HBV DNA polymerase do not occur naturally (unpub-
lished observations). Generally e¡ective in suppressing HBV
viral replication, long-term lamivudine (negative enantiomer
of 2P-dideoxy-3P-thiacytidine, or (-)3TC) treatment has, how-
ever, led to the emergence of unresponsive HBV strains [40].
Mutations in the catalytic region of HBV DNA polymerase,
in particular Met-552-Ile or Met-552-Val in the conserved
‘Tyr-Met-Asp-Asp’ (‘YMDD’) motif that comprises part of
the active site (domain C) of the reverse transcriptase ([39],
Fig. 2B), have been associated with the loss of inhibitory
activity of lamivudine [40]. It is interesting to note that a
mutation within the same ‘YMDD’ motif that is conserved
in all reverse transcriptases [39] is also associated with viral
resistance to (-)3TC in human immunode¢ciency virus (HIV)
[41]. On the other hand, the major famcyclovir resistant mu-
tations (Val-521-Leu and Leu-528-Met) are clustered within
the B domain of the DNA polymerase ([42], Fig. 2B). In
Fig. 2. Structural organization of HBV viral proteins. Functional
domains of each HBV viral protein are shown by various boxes in
shade. The positions of HBsAg (A) in relation to HBV DNA poly-
merase (B) and that between precore/core (C) with HBX (D) corre-
spond to their genomic overlapping. (A) HBsAg. The size in amino
acid residues is indicated (1^400). Positions of preS1 (1^118), preS2
(119^174) and the major HBsAg (175^400) are indicated below the
box. The position of the antigenic major hydrophilic loop in rela-
tion to the full-length HBsAg is also indicated. The corresponding
position of this antigenic loop within the major HBsAg is from ami-
no acid 100 to 160. (B) HBV DNA polymerase. The size in amino
acid residues is indicated (1^832). Positions of each of the four
functional domains are indicated by numbers below the box: 1^177
(priming), 179^335 (spacer), 336^679 (reverse transcriptase) and
680^832 (RNAse H). In addition, the catalytic domain of the re-
verse transcriptase with the ¢ve conserved motifs (A^E in shade) is
indicated in the enlarged box. The numbers below (421^600) the en-
larged box represent the position of the catalytic domain and the
position of the YMDD552 motif that is involved in viral resistance
to anti-viral therapy (see text) is also indicated. (C) Precore/core.
The size in amino acid residues is indicated (1^183). The position of
precore (preC) is indicated in shade and numbered (1^29), while the
position of core is represented by numbers (30^183) below the box.
The nuclear localization and region involved in DNA binding are in
shade and numbers from 155 to 177 within the core protein. (D)
HBX protein. The size in amino acid residues is indicated (1^154).
The box represents the HBX protein, while the adjacent solid line
represents the DNA sequence of HBV DNA with the encapsulation
signal (see text) in an oval form. The transactivation domain span-
ning residues 46^145 is indicated. The split Kunitz-like domain is
also indicated (61^69 and 131^142).
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contrast to vaccine escape HBsAg mutants, recent reports
indicate that these anti-viral resistant polymerase mutants
are replication defective, probably due to the location of mu-
tations within the crucial catalytic domain [43] and appear to
be overtaken by wild-type HBV upon cessation of anti-viral
therapy [44].
Despite their overlapping location on the viral genome, the
major antigenic ‘a’ determinant on HBsAg is located in the
variable linker region between the two conserved domains A
(amino acid 410^426) and B (amino acid 498^528) of the
DNA polymerase ([39], Fig. 2B). Many reported anti-viral
resistant polymerase mutants give rise to concurrent HBsAg
mutations outside the ‘a’ determinant (Glu-164-Asp, Trp-196-
Ser/Leu and Trp-196-stop codon) [4]. Although these muta-
tions do not result in alterations in the viral antigenicity, the
generation of potential vaccine escape mutations has been
identi¢ed in a lamivudine-treated Singapore patient who car-
ries both the YIDD polymerase mutation and an independent
Gly-130-Asp HBsAg mutation [45]. While these new lamivu-
dine resistant HBV mutants are sensitive to other nucleoside
analogs that inhibit the reverse transcription at a di¡erent
level (i.e. gancyclovir) [45], their emergence should require
further monitoring as they are capable of escaping detec-
tion/neutralization and are resistant to anti-viral therapy.
4. Precore/core and mutants
The structural nucleocapsid protein HBcAg consists of
185 amino acid residues plus an additional 29 amino-terminal
residues (precore) ([46], Fig. 2C). It is involved in capsid for-
mation, packaging of the pregenome reverse transcriptase
complex, tra⁄cking of the capsid in the cell and envelopment
[47]. Serum appearance of antibodies against the nucleoside
(anti-HBc) is indicative of the HBV infection. The HBe anti-
gen, a 17 kDa secretory protein found in serum during active
HBV replication, is encoded by the same core gene but lacks
the arginine-rich C-terminal 35 amino acid residues [48]. Var-
ious motifs have been identi¢ed including nuclear localization
and B- and T-cell epitopes [46].
While large overlaps can be seen among HBV DNA polym-
erase, HBsAg and HBX genes, a signi¢cant part of the core
gene is not covered by any other coding regions (Fig. 1).
There should therefore be decreased constraints for naturally
occurring mutations in the core gene as compared with those
found in overlapping genes (e.g. DNA polymerase and
HBsAg) [49], which is re£ected by the numerous naturally
occurring mutations that are detected in chronic HBV carriers
and those with fulminant hepatitis [50]. On the other hand,
treatment with interferon that promotes viral clearance by
immune stimulation also results in mutations on the B-cell
epitopes of the core protein [51]. Mutations are also found
in the precore promoter leading to an enhanced viral replica-
tion [52] and a precore stop codon mutation (G-A at nucleo-
tide 1896) that results in an increased stability of the encap-
sulation signal (Fig. 2D) that is crucial for the pregenomic
encapsulation and the initiation of HBV DNA synthesis [53].
While these precore stop codon mutants are frequently
found in many Asian patients with fulminant hepatitis ([54^
57], Table 1) including those from Singapore (unpublished
data), their absence in European patients [58] suggests that
other mechanisms may have contributed to the pathogenesis
of fulminant hepatitis. Vertical transmission of such precore
mutants with an enhanced viral replication activity has been
found to cause hepatitis in newborns [59].
5. HBX and mutants
HBX, the smallest HBV viral protein with 154 amino acid
residues, has been reported to interact with a wide range of
cellular proteins [60], among which transcription activators
that are involved in the activation of protooncogenes (c-jun)
and growth control (Egr-1) [61,62]. In addition to the domains
that are important for the transactivation and in vitro trans-
forming activities [63,64], there is also a split but functional
Kunitz-like serine protease inhibitor domain ([65], Fig. 2D).
The function of HBX as a protease inhibitor has been further
strengthened by the recent identi¢cation of the proteasome as
its new target [66,67]. These ¢ndings suggest a more general
role for HBX in inhibiting cellular processes of protein deg-
radation.
Although the exact function of HBX in the pathogenesis of
HBV-related HCC is not clear, it has been shown that HBX is
Fig. 3. Predicted features of the secondary structure of HBsAg. (A)
Topological model of the major hydrophilic loop. The positions of
the two predicted transmembrane helices upstream and downstream
of the major hydrophilic loop are indicated by numbers (80^100
and 160^180, respectively). The amino acid residues forming the
two-loop ‘a’ determinant are represented by open circles on the sur-
face of the lipid membrane, while residue 145 where the most com-
mon vaccine escape mutation occurs is indicated by a black circle.
The membrane represents the bi-layered lipid of the viral particle.
(B) Predicted antigenicity pro¢le of wild-type and Gly-145-Arg mu-
tant HBsAg. The prediction analysis is according to the Hoop/
Woods method (Omiga system), with seven amino acid residues
(average size of an epitope) as the scanning window. Changes of
antigenicity are seen in Gly-145-Arg HBsAg mutant and labelled in
the discontinued line.
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able to transform in vitro NIH3T3 ¢broblasts and di¡erenti-
ated murine hepatocytes. When expressed in transgenic mice,
HBX can induce HCC in certain lines [68] but it appears to
assume an indirect action in cooperation with other cellular
oncogenic factors in the liver oncogenesis [69,70]. Frequent
mutations and deletions have been identi¢ed in the small
HBX protein [60,71]. New mutations in HBX from Asian
patients (including Thailand and Korea) were previously iden-
ti¢ed in a systematic study [72]. A novel class of HBX mu-
tants has recently been identi¢ed in liver tissue of Singapore
HCC patients (Table 1), some of these integrated HBV se-
quences also carried HBsAg mutations that may be associated
with the development of HCC [37].
6. Conclusion
There is today an increasing understanding of the many
mutations occurring in the hepatitis B viral genome. While
some HBsAg mutants have appeared to be associated with
vaccination or anti-viral therapy, others have existed naturally
either in asympatomatic carriers or patients with serious liver
diseases. Some of these mutations located in viral proteins
such as HBsAg, precore and HBX have been found in acute
fulminant hepatitis, cirrhosis and HCC. These human HBV
mutants can be autonomous in behavior but capable of caus-
ing serious harm. Further molecular characterization of these
various mutants should provide helpful information in devel-
oping better detection systems as well as more e¡ective pro-
phylactic and therapeutic agents against these mutants.
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